Research Use Only (RUO). For laboratory research only. Not for human or veterinary use.
Weight & Metabolism
Strength: 500 mcg
Tesofensin is studied around appetite and body weight, but it works differently from the GLP-1 compounds: it acts in the brain, on the signals that regulate hunger. It is a pill, not a peptide.
The more products, the bigger the discount
Free shipping: Greece from €50, Cyprus and Bulgaria from €100, France, Germany, Italy, Belgium, Netherlands and Spain from €200. Details
This product is intended exclusively for laboratory research use. It is not intended for human consumption, diagnosis, treatment, or prevention of disease.
Documentation on request
There is no published document for this specific SKU variant at the moment.
Contact us about documentationResearch overview
Research focuses on topics such as:
Areas of research — not a promise of results.
The GLP-1 compounds press a "switch" in the gut. Tesofensin works higher up, in the brain. Same research topic, an entirely different route.
Batch documentation and COA, where available, are linked to the specific product batch and SKU.
This product is intended exclusively for laboratory research use. It is not intended for human consumption, diagnosis, treatment, or prevention of disease.
Product profile
3
monoamine transporters at once — norepinephrine, dopamine, serotonin
~234 hours
half-life estimated in a population model (Lehr et al., 2007)
18–77%
dopamine transporter occupancy measured by PET (Appel et al., 2013)
≥98%
active substance purity by HPLC
Research context
Tesofensine is not a peptide. It is a small molecule that acts on the brain.
It began as an experimental drug for neurological conditions. It failed there — but volunteers were losing weight. So it changed course.
Development code NS-2330. A reuptake inhibitor of three neurotransmitters: noradrenaline, dopamine and serotonin.
In the brain, three chemical messengers help set how hungry we feel.
Tesofensine blocks their 'recycling', so they stay active longer. The satiety signal strengthens and appetite drops.
In 2024 it was shown to silence specific GABAergic neurons of the lateral hypothalamus, reducing the drive to eat (Perez et al., PLoS One).
The pivotal study remains the 2008 phase II trial in the Lancet, with 203 participants.
In 2022 a combination with a heart-rate agent was tested in a rare obesity caused by hypothalamic injury, adding further weight loss.
−9.2%
weight, wk 24, Lancet 2008
+7.4
beats/min (mid dose)
203
participants, phase II
2008
last large trial
The loss was nearly double that of the drugs approved at the time — but the phase III for general obesity was never completed.
The Lancet authors themselves kept a reservation: the findings need confirmation in phase III. That was never done for general obesity.
There is a cardiovascular signal: at the mid dose heart rate rose by 7.4 beats per minute.
It is sold online as a 'supplement', but it is a prohibited substance in sport (WADA, class S6).
Astrup et al., Lancet, 2008 (TIPO-1 trial); Tesomet combination, Huynh et al., 2022; urinary detection, Krug et al., 2026.
Used in a controlled laboratory setting for in vitro inhibition studies at the dopamine (DAT), norepinephrine (NET) and serotonin (SERT) transporters, for comparative work against selective reuptake inhibitors, for structural and computational binding studies at the dopamine transporter, for LC-MS analytical method development and metabolite identification work, and for identity and purity confirmation by HPLC and mass spectrometry.
Research Use Only — For laboratory research exclusively. Tesofensin is NOT approved as a medicine by the European Medicines Agency (EMA), the FDA, or the Greek National Organisation for Medicines (EOF). It is not a medicinal product, a dietary supplement, or a food. It is not intended for human or veterinary use, nor for the diagnosis, treatment, prevention or mitigation of any disease or condition. No dosing, protocols or administration guidance are provided. This is a psychoactive molecule with documented dose-dependent effects on heart rate and blood pressure; its development has not progressed beyond Phase II. It is listed under class S6 (stimulants) on the World Anti-Doping Agency's Prohibited List. The study data referenced here are presented for scientific information only and do not transfer to any non-research use. Sale is intended for research institutions and laboratories only.
Comparison
| Feature | Tesofensin (this product) | Semaglutide | Orforglipron |
|---|---|---|---|
| Where it acts | In the brain — blocks monoamine transporters at the synaptic cleft | At GLP-1 receptors (pancreas, gut, brain) | At GLP-1 receptors |
| Mechanism | Triple reuptake inhibition of norepinephrine, dopamine and serotonin | GLP-1 receptor agonist (incretin pathway) | GLP-1 receptor agonist (incretin pathway) |
| Chemical nature | Small molecule, a tropane derivative (~328 g/mol) | A 31-amino-acid peptide | Non-peptide small molecule |
| Route in the literature | Oral | Mainly injectable (an oral form also exists) | Oral |
| Maturity of the evidence | Reached Phase II — no completed Phase III programme | Completed Phase III programme | Phase III programme ongoing |
| Recorded adverse-effect profile | Dose-dependent increases in heart rate and blood pressure; dry mouth, insomnia, nausea, mood changes | Predominantly gastrointestinal (nausea, vomiting, diarrhoea) | Predominantly gastrointestinal |
| Regulatory status | No EMA/FDA/EOF approval; listed under WADA class S6 stimulants | An approved medicinal product in many countries | Under regulatory evaluation |
| Product form | Oral capsule | Lyophilized powder | Capsule / tablet |
References
Category comparison
Product information